The first half of 2025 saw a notable increase in seed and Series A funding rounds within the biopharma sector, totaling $4.7 billion, although fewer companies accounted for a larger share of the capital raised. Despite a concentration in early-stage investment, the sector continues to attract significant venture capital, underpinning ongoing innovation and company formation. Key financing data highlights the active investment landscape sustaining biopharma development globally.